Clinically relevant quality measures for risk factor control in primary care: a retrospective cohort study

Table 3 Patients with poorly controlled hypertension, dyslipidemia, or diabetes mellitus, who had subsequent therapy modifications within a 6-months or 12 months-period

	Patients with poorly controlled hypertension				Patients with poorly controlled dyslipidemia				Patients with poorly controlled diabetes mellitus
	6 Months		12 Months		6 Months		12 Months		6 Months		12 Months
	n	%	n	%	n	%	n	%	n	%	n	%
Appropriate clinical action	211	54.0	240	61.4	67	29.0	87	37.7	46	78.0	50	84.7
Any therapy modification	193	49.4	238	60.9	55	23.8	77	33.3	44	74.6	50	84.7
Increase class	121	30.9	153	39.1	43	18.6	64	27.7	26	44.1	30	50.8
Increase dose	103	26.3	135	34.5	15	6.5	23	10.0	31	52.5	36	61.0
Switch class^†	30	7.7	49	12.5	0	0.0	2	0.9	6	10.2	10	16.9
Several modifications	55	14.1	88	22.5	3	1.3	11	4.8	19	32.2	26	44.1
Return to control WO modification^‡	18	4.6	2	0.5	12	5.2	10	4.3	2	3.4	0	0.0
Inappropriate clinical action	180	46.0	151	38.6	164	71.0	144	62.3	13	22.0	9	15.3
No modification, return to near control^‡	25	6.4	9	2.3	38	16.5	27	11.7	1	1.7	3	5.1
No modification, no return^‡	120	30.7	134	34.3	40	17.3	40	17.3	7	11.9	2	3.4
No measurement, no modification	35	9.0	8	2.0	86	37.2	77	33.3	5	8.5	4	6.8

LDL = low-density lipoprotein. ^†A switch to different drug class was counted when a new class of medication for the condition was added, but the total number of drug classes remained the same. ^‡Categories of control with levels of control, near and poor control for hypertension, dyslipidemia and diabetes mellitus are based on N. Rodondi et al. [5]. This category includes patients without visit or measurements.

ISSN: 1472-6963